58 results about "Hypercalcinemia" patented technology

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

Disclosed is a tape-type transdermally absorptive preparation which has excellent transdermal absorption, high safety and high usability, and which is suitable for the treatment of a disorder of bone / calcium metabolism, such as osteoporosis, osseous Paget's disease and hypercalcemia associated with a malignant tumor. Specifically disclosed is a tape-type transdermally absorptive preparation characterized by containing a bisphosphonate or a derivative thereof. Preferably, the tape-type transdermally absorptive preparation comprises a support sheet and an adhesive layer laminated on one surface of the support sheet, wherein the adhesive sheet comprises: 100 parts by weight of an acrylic copolymer which comprises 50 to 88 wt% of acrylic acid, 8 to 40 wt% of 2-ethylhexyl acrylate and 1 to 42 wt% of a polar monomer (excluding acrylic acid); 150 to 600 parts by weight of a polyhydric alcohol; and a pharmaceutically effective amount of a bisphosphonate.

The present invention relates to an agent for increasing BMD characterized by use of a cathepsin K inhibitor as a bone resorption inhibitor in combination with a type of PTH as a bone formation stimulator. This agent for increasing BMD is useful for the treatment of osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcemia, osteometastasis of carcinoma, periodontal disease, bone Paget's disease and other bone metabolic diseases. For example, as the cathepsin K inhibitor, there can be mentioned a compound of formula (W) and a salt thereof, etc.

The present disclosure provides a method of treating malignant rhabdoid tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an enhancer of zeste homolog 2 (EZH2) inhibitor. In certain embodiments of the method, the malignant rhabdoid tumor is small cell carcinoma of the ovary with hypercalcemia (SCCOHT), and the EZH2 inhibitor is tazemetostat (also known as Tazemetostat).